00887nam0-22003251i-450 99000086431040332120191029134712.00-672-30286-1000086431FED01000086431(Aleph)000086431FED0100008643120001010d1994----km-y0itay50------baengUSy-------001yyC Programmer's guide to serial communicationsJ. Campbell2 ed.IndianapolisSAMS Publishing1994XXIII, 952 p.23 cm005.1Campbell,Joe<1944- >42750ITUNINARICAUNIMARCBK99000086431040332102 50 C 356924FINBNFINBNC Programmer's guide to serial communications1564414UNINAING0102128nam 2200589 a 450 991079176770332120200520144314.01-61728-630-3(CKB)2560000000068789(EBL)3020732(SSID)ssj0000467205(PQKBManifestationID)12192775(PQKBTitleCode)TC0000467205(PQKBWorkID)10489987(PQKB)10610926(MiAaPQ)EBC3020732(Au-PeEL)EBL3020732(CaPaEBR)ebr10680870(OCoLC)698081866(EXLCZ)99256000000006878920100419d2010 uy 0engur|n|---|||||txtccrBeneficial effects of perhexiline in cardiovascular disease states[electronic resource] /Yuliy Y. Chirkov, Aaron L. Sverdlov and John D. HorowitzNew York Nova Biomedical/Nova Science Publishers20101 online resource (53 p.)Cardiology research and clinical developmentsDescription based upon print version of record.1-61668-977-3 Includes bibliographical references (p. [31]-38) and index.Clinical applications of perhexiline -- Pharmacokinetics and toxicity of perhexiline -- Pharmacology of perhexiline -- Conclusion and future perspectives.Cardiology research and clinical developments series.PerhexilineTherapeutic useAngina pectorisChemotherapyCardiovascular agentsPerhexilineTherapeutic use.Angina pectorisChemotherapy.Cardiovascular agents.616.1/22061Chirkov Yuliy Y1564692Sverdlov Aaron L1564693Horowitz John D1564694MiAaPQMiAaPQMiAaPQBOOK9910791767703321Beneficial effects of perhexiline in cardiovascular disease states3833889UNINA